Hls Therapeutics (TSE:HLS) has released an update.
HLS Therapeutics Inc., a North American pharmaceutical company, is set to discuss its fourth quarter and full-year 2023 financial results in a conference call on March 14, 2024, led by CEO Craig Millian and Interim CFO John Hanna. Interested parties can access the conference via webcast or traditional phone lines, with a taped replay available for two weeks after the event. This announcement should attract investors looking to understand the company’s recent performance and future outlook.
For further insights into TSE:HLS stock, check out TipRanks’ Stock Analysis page.
